Keyphrases
Parkinson's Disease
93%
Dopamine
45%
Levodopa
36%
Patients with Parkinson's Disease
24%
Regional Cerebral Blood Flow (rCBF)
23%
Striatum
21%
L-DOPA
19%
Striatal
18%
Dopaminergic Neurons
16%
Multiple Sclerosis
16%
Neurodegenerative Diseases
16%
Neurotrophic Factors
15%
Oxidative Stress
15%
Human Mesenchymal Stem Cells (hMSCs)
15%
6-hydroxydopamine (6-OHDA)
14%
Mesenchymal Stem Cells
13%
Dopaminergic Neurotoxicity
13%
Response Fluctuations
13%
Parkinsonism
13%
Apoptosis
12%
Antioxidant
12%
Neurotoxicity
12%
Induced Apoptosis
11%
Levodopa Therapy
10%
Experimental Autoimmune Encephalomyelitis
9%
Nigrostriatal System
9%
Parkinson Patients
9%
DJ-1
8%
Amyotrophic Lateral Sclerosis
8%
Propranolol
8%
Cell Death
8%
Dopamine Agonist
8%
Neurotoxin
7%
Transplantation
7%
PC12 Cells
7%
Idiopathic Parkinson's Disease
7%
Apomorphine
7%
Neuronal Cells
6%
Neuroprotection
6%
Parkinsonian
6%
Substantia Nigra
6%
Unified Parkinson's Disease Rating Scale (UPDRS)
6%
Central Nervous System
6%
Contralateral Hemisphere
6%
Advanced Parkinson's Disease
6%
Stem Cells
6%
Nigrostriatal Neurons
5%
Dyskinesia
5%
Huntington's Disease
5%
Quinolinic Acid
5%
Neuroscience
Parkinson's Disease
100%
L-DOPA
37%
Dopaminergic
34%
Striatum
26%
Mesenchymal Stem Cell
23%
Programmed Cell Death
22%
Parkinsonism
17%
Neurodegenerative Disorder
17%
Oxidative Stress
16%
Multiple Sclerosis
16%
Antioxidant
15%
Dopaminergic Neuron
14%
Neurotrophic Factor
14%
Neurotoxicity
13%
Oxidopamine
13%
Cell Death
12%
Stem Cell
12%
Cerebrovascular Accident
11%
In Vivo
10%
Experimental Autoimmune Encephalomyelitis
9%
DOPA
9%
Treatment of Parkinson's Disease
8%
Blood Plasma
7%
Central Nervous System
7%
Neuroprotective Agent
7%
Neurotransmitter
7%
Neurotoxin
7%
Amyotrophic Lateral Sclerosis
7%
Mitochondrial Permeability Transition Pore
6%
Corticosterone
6%
Dystonia
6%
Neuronal Cell Death
6%
Neuroprotection
6%
Norepinephrine
6%
Tetrahydropyridine
6%
Propranolol
6%
Homovanillic Acid
5%
Quinolinic Acid
5%
Dopamine Agonist
5%
Kainic Acid
5%
Reactive Oxygen Species
5%
Single-Photon Emission Computed Tomography
5%
In Vitro
5%
Carboxy-Lyases
5%
Cell Therapy
5%
Nervous System Disorder
5%
Behavior (Neuroscience)
5%
Substantia nigra
5%
Brain Ischemia
5%
Huntington's Disease
5%